Innovating Works

EicoMet

Financiado
Targeting eicosanoid metabolism to overcome tumor immunosuppression
The field of cancer immunotherapy has witnessed exciting therapeutic advances in the last decade, but still a large fraction of patients is not responsive and several cancer types are refractory to this therapy. The presence of a... The field of cancer immunotherapy has witnessed exciting therapeutic advances in the last decade, but still a large fraction of patients is not responsive and several cancer types are refractory to this therapy. The presence of a strongly immunosuppressive environment is a likely explanation for the suboptimal efficacy of immunotherapy. One of the most abundant and immune suppressive population in the tumor microenvironment (TME) is represented by tumor-associated macrophages (TAMs). Therefore, several strategies that sculpt the TAM phenotype away from their immunosuppressive state are expected to become the next generation immunotherapies. Supported by the ERC consolidator grant ImmunoFit, we recently unveiled that the metabolic editing of the TME via the pharmacological and genetic inhibition of HPGDS in macrophages (an enzyme involved in the production of prostaglandin D2 from arachidonic acid), represents a novel therapeutic strategy to sculpt TAMs away from their immunosuppressive state, increase infiltration and fitness of CD8+ T cells and NK cells, and promote tumor vessel normalization. This change in the TME upon HPGDS inhibition overcomes resistance to current immunotherapeutic regimens in melanoma and other cancer indications. This proposal aims to de-risk HPGDS targeting by delivering a lead compound with proven efficacy in several preclinical models. The deliverables of this project will open-up a window of opportunities in immune-oncology and lead to novel combination therapies by increasing the potency of the current therapeutic approaches. ver más
31/07/2025
VLAAMS INSTITUUT...
150K€
Perfil tecnológico estimado
Duración del proyecto: 19 meses Fecha Inicio: 2023-12-15
Fecha Fin: 2025-07-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-15
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS
Cerrada hace 1 año
Presupuesto El presupuesto total del proyecto asciende a 150K€
Líder del proyecto
VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5